The Impact of Anemia of Chronic Disease on Chronic Obstructive Pulmonary Disease Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypothesis:

The first part of the study is a survey on the prevalence of anemia of chronic disease (ACD) among COPD patients. The 2nd and 3rd part will test 2 null hypotheses (Ho): 1.serum inflammatory markers and plasma erythropoietin do not differ between COPD patients with and without ACD and 2. exercise capacity does not differ between COPD patients with and without ACD.

Rationale-Aim:

ACD is an immune driven disorder, developing in subjects suffering from chronic inflammatory diseases. COPD is a disorder very likely to be associated to ACD due to its systemic inflammatory dimension. Currently, data on the prevalence of ACD and on the level of inflammatory markers which are implicated in the pathogenesis of ACD in COPD subjects are limited and controversial. Furthermore, there is no data on the effect of ACD on exercise capacity of COPD subjects.

Based to the aforementioned, this study has three goals:

1. to determine the prevalence and the epidemiologic characteristics of ACD in a population of clinical stable COPD patients
2. to investigate whether the levels of serum inflammatory markers and of plasma erythropoietin differ between COPD patients with ACD and without ACD
3. to determine potential differences regarding the aerobic exercise capacity between these two groups, using the cardiopulmonary exercise testing (CPET).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nutritional Enhancement in Chronic Obstructive Pulmonary Disease (COPD)

NCT00884299

Chronic Obstructive Pulmonary Disease

COMPLETED NA

The Anti-oxidant Effects of N-Acetylcysteine in Chronic Obstructive Pulmonary Disease (COPD)

NCT03956888

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE3

Airway Inflammation, Symptoms and Lung Function in COPD

NCT01216592

Chronic Obstructive Pulmonary Disease

COMPLETED

Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific

NCT03151395

Respiratory Disorders

COMPLETED NA

Clinical Features and Airways Inflammation in Never Smokers and Smokers With COPD

NCT03274791

COPD Airway Obstruction Inflammation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD patients with ACD

In the 1st part of this clinical study the prevalence ACD in COPD subjects will be estimated in a consecutive population of COPD subjects who will visit the hospital's pulmonary clinics as outpatients. During the first visit, subjects will give a detailed medical history and will undergo clinical examination and pulmonary function testing 15 minutes post-bronchodilation. Eligible patients will then undergo peripheral venous blood analysis. The first 30 COPD subjects from the population described above, fulfilling the criteria of ACD will constitute the first arm (group of "cases").ACD is defined by low Hb levels (men: \<13 mg/dl, women: \<12 mg/dl), no other cause of anemia present, normal or increased serum ferritin and decreased total iron binding capacity.

Group Type OTHER

maximal cardiopulmonary exercise testing

Intervention Type PROCEDURE

Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).

peripheral blood samples

Intervention Type PROCEDURE

Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.

COPD patients without ACD

Thirty matched patients with COPD without ACD from the initial cohort will constitute the second arm (the "controls")

Group Type OTHER

maximal cardiopulmonary exercise testing

Intervention Type PROCEDURE

Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).

peripheral blood samples

Intervention Type PROCEDURE

Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

maximal cardiopulmonary exercise testing

Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).

Intervention Type PROCEDURE

peripheral blood samples

Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1st part of the study:

* COPD clinically stable (patients with post-bronchodilation FEV1/FVC \<0.7 and no acute exacerbations, hospital admissions or treatment changes in the last 3 months).
* 2nd and 3rd part:
* As above.

Exclusion Criteria

* 1st part of the study:

* history of asthma,
* history of respiratory infection in the last 3 months
* 2nd and 3rd part: As above and additionally:

* history of malignancy or haematologic disorder
* acute or chronic inflammatory disease
* systematic or autoimmune disorder
* thyroid disease
* liver cirrhosis
* heart failure (ejection fraction \<55%)
* history of gastrointestinal or other hemorrhage
* renal failure (GFR\<60 ml/min/1.73m2)
* blood transfusion in the last 4 months
* administration of cortisone in the last month
* pregnancy
* mental impairment
* medical conditions which are contraindications to exercise testing, such as:
* acute myocardial infarction (in the last 6 months)
* unstable angina
* left main coronary stenosis or its equivalent
* syncope
* symptomatic severe aortic stenosis or other moderate stenotic valvular disease
* uncontrolled arrhythmias causing symptoms
* acute pulmonary embolus or pulmonary infarction
* thrombosis of lower extremities
* suspected dissecting aneurysm
* pulmonary oedema
* room air desaturation at rest \<85%
* severe untreated arterial hypertension at rest (\>200 mmHg systolic, \>120 mmHg diastolic)
* high degree atrioventricular block
* hypertrophic cardiomyopathy and
* orthopedic impairment that compromises exercise performance

Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No